anticorps BBGD, anticorps THMD2, anticorps THTR2, anticorps thtr2, anticorps MGC52872, anticorps MGC89434, anticorps si:dkey-223n17.4, anticorps slc19a3, anticorps A230084E24Rik, anticorps AI788884, anticorps ThTr2, anticorps solute carrier family 19 member 3, anticorps solute carrier family 19 member 3 L homeolog, anticorps solute carrier family 19 (thiamine transporter), member 3, anticorps thiamine transporter 2, anticorps solute carrier family 19 (thiamine transporter), member 3b, anticorps solute carrier family 19, member 3, anticorps thiamine transporter 2-like, anticorps SLC19A3, anticorps Slc19a3, anticorps slc19a3.L, anticorps slc19a3, anticorps LOC486151, anticorps slc19a3b, anticorps LOC100230080
Sujet
This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD), a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild mental retardation, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.